Tempus AI, Inc. — Third Quarter 2026 Earnings Summary

Tempus AI, Inc. reported third-quarter 2026 total revenue of $411.5 million, representing a 23% increase compared to the same period in 2025. The company achieved an Adjusted EBITDA of $25.6 million and a net loss of $14.9 million, driven by $50.8 million in stock-based compensation and $42.8 million in unrealized gains on marketable securities. Oncology volume growth accelerated to 32%, while Data and Applications revenue grew by 33%, contributing to an increased full-year 2026 revenue guidance of $1.60 to $1.605 billion. Strategic developments included a multi-year collaboration with Merck and Moderna for neoantigen therapy commercialization and a data licensing agreement with BMS valued at over $550 million year-to-date.